...
首页> 外文期刊>Frontiers in Genetics >Investigation of the Genome-Wide Genetic and Epigenetic Networks for Drug Discovery Based on Systems Biology Approaches in Colorectal Cancer
【24h】

Investigation of the Genome-Wide Genetic and Epigenetic Networks for Drug Discovery Based on Systems Biology Approaches in Colorectal Cancer

机译:基于系统生物学方法在结肠直肠癌中的药物发现基因组遗传和表观遗传网络的研究

获取原文
           

摘要

Colorectal cancer (CRC) is the third most commonly diagnosed type of cancer worldwide. The mechanisms leading to the progression of CRC are involved in both genetic and epigenetic regulations. In this study, we applied systems biology methods to identify potential biomarkers and conduct drug discovery in a computational approach. Using big database mining, we constructed a candidate protein-protein interaction network and a candidate gene regulatory network, combining them into a genome-wide genetic and epigenetic network (GWGEN). With the assistance of system identification and model selection approaches, we obtain real GWGENs for early-stage, mid-stage, and late-stage CRC. Subsequently, we extracted core GWGENs for each stage of CRC from their real GWGENs through a principal network projection method, and projected them to the Kyoto Encyclopedia of Genes and Genomes pathways for further analysis. Finally, we compared these core pathways resulting in different molecular mechanisms in each stage of CRC and identified carcinogenic biomarkers for the design of multiple-molecule drugs to prevent the progression of CRC. Based on the identified gene expression signatures, we suggested potential compounds combined with known CRC drugs to prevent the progression of CRC with querying Connectivity Map (CMap).
机译:结肠直肠癌(CRC)是全世界第三种最常见的癌症类型。导致CRC进展的机制涉及遗传和表观遗传法规。在这项研究中,我们应用了系统生物学方法来识别潜在的生物标志物并以计算方法进行药物发现。使用大数据库挖掘,我们构建了候选蛋白质 - 蛋白质相互作用网络和候选基因调节网络,将它们组合成基因组族遗传和表观遗传网络(GWGEN)。在系统识别和模型选择方法的帮助下,我们获得了早期,中阶段和后期CRC的真正的GWGENs。随后,我们通过主要网络投影方法从其真正的GWGENs提取CRC的每个阶段的核心GWGENs,并将它们投射到基因的Kyoto百科全书和基因组途径以进一步分析。最后,我们比较了这些核心途径,导致CRC的每个阶段产生不同的分子机制,并确定了用于设计多分子药物以防止CRC进展的致癌生物​​标志物。基于所鉴定的基因表达签名,我们建议潜在化合物与已知的CRC药物联合,以防止CRC的进展与查询连接图(CMAP)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号